139 results
8-K
EX-99.1
ABBV
Abbvie Inc
26 Apr 24
AbbVie Reports First-Quarter 2024 Financial Results
7:43am
compared to 29 percent of patients receiving placebo in combination with a 52-week steroid taper regimen. Rinvoq’s safety profile in GCA was generally … consistent with that in approved indications, and no new safety signals were identified.
AbbVie announced positive topline results from the Phase 3b/4
8-K
EX-5.1
ABBV
Abbvie Inc
26 Feb 24
Other Events
5:08pm
health or safety reasons or otherwise (including a pandemic).
This letter speaks only as of its date and is delivered in accordance
8-K
EX-99.1
nnu2xvhg23ze520sfvid
2 Feb 24
AbbVie Reports Full-Year and Fourth-Quarter 2023 Financial Results
7:51am
8-K
EX-99.1
uc9hfp9szr sz
6 Dec 23
AbbVie to Acquire Cerevel Therapeutics in Transformative Transaction to Strengthen Neuroscience Pipeline
5:28pm
8-K
EX-99.2
oo5cm
6 Dec 23
AbbVie to Acquire Cerevel Therapeutics in Transformative Transaction to Strengthen Neuroscience Pipeline
5:28pm
8-K
EX-99.2
1c3bunwm
30 Nov 23
AbbVie to Acquire ImmunoGen, including its Flagship Cancer Therapy ELAHERE® (mirvetuximab soravtansine-gynx), Expanding Solid Tumor Portfolio
8:47am
8-K
EX-99.1
t5z3xmodewi7vj6wtde
27 Oct 23
AbbVie Reports Third-Quarter 2023 Financial Results
7:49am
8-K
EX-99.1
yg83oe
27 Jul 23
AbbVie Reports Second-Quarter 2023 Financial Results
7:45am
PX14A6G
xpar 3no8kus9lhb
4 May 23
Letter to shareholders
8:08am
8-K
EX-99.1
tb9e54fv36 l4
27 Apr 23
AbbVie Reports First-Quarter 2023 Financial Results
7:36am
8-K
EX-99.1
dxtl8j
28 Oct 22
AbbVie Reports Third-Quarter 2022 Financial Results
7:48am
8-K
EX-3.1
kx1m9opp2ly
14 Oct 22
Departure of Directors or Certain Officers
5:02pm